Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

ncing, we have raised the necessary funds to build on the pioneering research and foundational intellectual property of our scientific founders for human cell reprogramming and to enable the commercialization of our pharmaceutical grade iPSC technology."

About OVP Venture Partners

For 26 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVP makes early stage investments in cleantech, digital biology and information technology. The firms' record of 52 liquidity events - including 22 IPOs - leads the region. OVP has over $750 million in capital under management and is currently investing its seventh fund. The firm has offices in Seattle, WA and Portland, OR. More information on the partnership is available at www.ovp.com.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit www.fatetherapeutics.
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Biomarkers and Clinigene International are set to unveil their ... 2013 AAPS/ National Biotechnology Conference May 20-22 ... Marina , San Diego, CA. ... company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity and ... 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and his ... Cardiovascular Institute have helped pioneer many breakthroughs in ... over the past three decades, from new disease-fighting medications ... artery stent implantation. , Today, AGH officials announced that ... in the study of a novel, first-of-its kind investigational ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... , May 18, 2010 , , ... - With Photo , , , ... safety device is now cleared by FDA for Home/Self use and is,consequently available to all ... dislodgement,during hemodialysis and its use has already improved in-clinic patient,safety. Optimizing safety conditions for home ...
... ... highly specialized metal tubing and innovative suppliers with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization ... off in many ways. One of the integral items that have helped to ...
... , ... METTLER TOLEDO announced a collaboration to combine their existing technologies to offer flow reactor ... production. , ... (PRWEB) -- ThalesNano and METTLER TOLEDO announced a partnership to offer flow reactor technology ...
Cached Biology Technology:Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 2METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 3METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 4
(Date:5/19/2013)... study reports that white men and women of European ... valgus) and lesser toe deformities, including hammer or claw ... estimate the heritability of foot disorders in humansappear in ... by Wiley on behalf of the American College of ... many as 60% of older adults have foot disorders ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... South, but the night belongs to the amphibians. In ... humidity and the sounds of wildlife. , The Southeast, ... salamanders, is the center of amphibian biodiversity in our nation. ... their symphonic choruses, the scientists of the U.S. Geological Survey,s ... , Amphibians, which rely on water for part ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... soon be able to wear contact lenses that continuously ... changing colours replacing the need to routinely draw ... by Chemical and Biochemical Engineering professor Jin Zhang at ... embedded into the hydrogel lenses. These engineered nanoparticles ...
... the deoxycytidine kinase (dCK) enzyme have defects in their ... T and B lymphocytes, the major players involved in ... UCLA,s Jonsson Comprehensive Cancer Center. The finding could ... body attacks itself, and possibly certain cancers of the ...
... common minerals in biology, including those in bones and shells, have ... making them behave as one giant crystal, even though they do ... grains of salt were spilled on a rug, yet instead of ... rotation. In a new study in the Journal ...
Cached Biology News:Enzyme necessary for development of healthy immune system 2Enzyme necessary for development of healthy immune system 3Dental delight: Tooth of sea urchin shows formation of biominerals 2Dental delight: Tooth of sea urchin shows formation of biominerals 3
Rat Normal Multiple Tissue Array 1 slide...
... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
...
...
Biology Products: